Novo Nordisk has announced plans to invest $4.1 billion to build a second plant in Clayton, and increase its capacity to produce injectable treatments for people suffering from obesity and other serious chronic diseases.

This expansion will double the combined surface area of its three existing facilities in North Carolina. It will also create 1,000 new jobs, in addition to the nearly 2,500 employees of the Danish laboratory already working in the region.

The facility is designed to be efficient and environmentally sustainable. Initial clearing and foundation work is already underway, and construction will be progressively completed between 2027 and 2029.

In 2024, Novo Nordisk plans to increase its current investment, aiming to allocate $6.8 billion to production, a significant increase on the previous year's investment of $3.9 billion.

Copyright (c) 2024 CercleFinance.com. All rights reserved.